LG
LGND.US Ligand Pharmaceuticals Incorporated
- Market cap
- USD 6.18B
- P/E
- 124.0x
- P/B
- 6.43x
- ROE
- 0.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LGND.US undervalued?
Graham numberThe Graham number of Ligand Pharmaceuticals Incorporated cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ligand Pharmaceuticals Incorporated fundamental analysis
No fundamental analysis for Ligand Pharmaceuticals Incorporated yet.
Ligand Pharmaceuticals Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma…
Full company profileLigand Pharmaceuticals Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ligand Pharmaceuticals Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 109M | 141M | 251M | 120M | 164M | 242M | 196M | 131M | 167M | 268M | 259M |
| Gross Profit | 103M | 136M | 245M | 109M | 133M | 179M | 143M | 96.3M | 156M | 261M | 248M |
| Operating Income | 43.9M | 68.1M | 164M | 807M | 37.5M | 104M | 3.04M | 11.9M | -22.6M | 47.2M | 13.6M |
| EBITDA | 55.2M | 80.3M | 236M | 876M | 56.7M | 143M | 81.2M | 101M | 40.8M | 193M | 18.8M |
| Net Income | -1.64M | 12.6M | 143M | 629M | -2.99M | 57.1M | -33.4M | 52.2M | -4.03M | 124M | 8.90M |
| EPS | -0.08 | 0.53 | 5.96 | 32 | -0.18 | 3.31 | -1.98 | 2.94 | -0.22 | 6.13 | 0.45 |
| Balance Sheet | |||||||||||
| Total Assets | 602M | 671M | 1.26B | 1.49B | 1.36B | 1.30B | 763M | 787M | 942M | 1.56B | 2.24B |
| Total Liabilities | 231M | 252M | 700M | 728M | 653M | 476M | 165M | 86.3M | 111M | 543M | 1.28B |
| Shareholders' Equity | 371M | 419M | 561M | 767M | 710M | 821M | 597M | 701M | 830M | 1.02B | 962M |
| Cash & Short-term Investments | 141M | 202M | 765M | 1.07B | 411M | 341M | 212M | 170M | 256M | 734M | 447M |
| Total Debt | 242M | 243M | 636M | 650M | 456M | 324M | 87.7M | 6.17M | 7.11M | 451M | 1.15B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 63.0M | 93.6M | 194M | -29.3M | 54.6M | 78.8M | 138M | 49.6M | 97.0M | 49.4M | 60.2M |
| Capital Expenditure | 28.3M | 7.15M | 11.9M | 2.55M | 4.46M | 8.76M | 17.9M | 53.8M | 19.6M | 452K | 528K |
| Free Cash Flow | 34.7M | 86.4M | 182M | -31.9M | 50.1M | 70.0M | 120M | -4.27M | 77.4M | 48.9M | 59.6M |
| Ratios | |||||||||||
| ROE | -0.4% | 3.0% | 25.6% | 82.0% | -0.4% | 7.0% | -5.6% | 7.4% | -0.5% | 12.2% | 0.9% |
| ROA | -0.3% | 1.9% | 11.4% | 42.1% | -0.2% | 4.4% | -4.4% | 6.6% | -0.4% | 8.0% | 0.4% |
| Net Profit Margin | -1.5% | 8.9% | 57.0% | 523.2% | -1.8% | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% | 3.4% |
| Debt to Equity | 0.65x | 0.58x | 1.13x | 0.85x | 0.64x | 0.40x | 0.15x | 0.01x | 0.01x | 0.44x | 1.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ligand Pharmaceuticals Incorporated dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 2, 2010
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 5.00M | 0.30 | - |
| 2021 | USD 15.3M | 0.89 | 26.8% |
| 2020 | USD 3.02M | 0.19 | - |
| 2019 | USD 3.00M | 0.15 | 0.5% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1603:1000 on Nov 2, 2022.
Who owns Ligand Pharmaceuticals Incorporated
- Insiders 2.87%
- Institutions 97.13%
- Public & others 0.00%
- Shares outstanding 20.0M
- Free float 19.6M
Top funds holding LGND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1.20M | 5.99% | -0.06% | Oct 2026 |
| Fidelity Contrafund | 1.05M | 5.26% | 0.00% | Sep 2026 |
| Invesco Discovery A | 685K | 3.43% | +8.13% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 609K | 3.04% | +0.31% | Sep 2026 |
| Franklin DynaTech Fund A | 600K | 3.00% | +3.64% | Sep 2026 |
| iShares Russell 2000 ETF | 509K | 2.55% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 426K | 2.13% | -2.75% | Sep 2026 |
| Janus Henderson Triton D | 419K | 2.09% | 0.00% | Sep 2026 |
| Nomura Small Cap Core I | 295K | 1.48% | -12.54% | Sep 2026 |
| Fidelity Small Cap Value Fund | 277K | 1.39% | -14.86% | Aug 2026 |
| Congress Small Cap Growth Institutional | 263K | 1.32% | -2.39% | Sep 2026 |
| Janus Henderson Venture D | 258K | 1.29% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 234K | 1.17% | -6.61% | Sep 2026 |
| Fidelity Small Cap Index | 220K | 1.10% | +0.15% | Aug 2026 |
| Fidelity Contrafund K6 | 219K | 1.10% | 0.00% | Sep 2026 |
| Neuberger Genesis Inv | 204K | 1.02% | +38.85% | Sep 2026 |
| Invesco S&P SmallCap Momentum ETF | 191K | 0.96% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 189K | 0.95% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 182K | 0.91% | -0.05% | Oct 2026 |
| DWS Small Cap Core S | 180K | 0.90% | -1.64% | Aug 2026 |
Top institutions holding LGND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 3.10M | 15.50% | +4.70% | Jun 2026 |
| Amvescap Plc. | 1.20M | 6.01% | +45.90% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.14M | 5.69% | +3.46% | Jun 2026 |
| Jupiter Topco LLC | 1.04M | 5.20% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 871K | 4.35% | +2.70% | Jun 2026 |
| State Street Corp | 827K | 4.13% | +6.12% | Jun 2026 |
| FMR Inc | 763K | 3.81% | +27.96% | Jun 2026 |
| Franklin Templeton Inc | 752K | 3.76% | +31.21% | Jun 2026 |
| Congress Asset Management Company, LLP | 660K | 3.30% | +30.77% | Jun 2026 |
| Geode Capital Management, LLC | 589K | 2.94% | +5.38% | Jun 2026 |
| Delaware Management Holdings Inc | 568K | 2.84% | -0.86% | Jun 2026 |
| Chicago Capital LLC | 553K | 2.77% | -1.47% | Jun 2026 |
| Stephens Inv Mgmt Group LLC | 476K | 2.38% | -3.85% | Jun 2026 |
| Massachusetts Financial Services Company | 376K | 1.88% | -8.69% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 363K | 1.82% | -15.39% | Sep 2026 |
| The Goldman Sachs Group Inc | 323K | 1.62% | -15.18% | Jun 2026 |
| Loomis, Sayles & Company LP | 292K | 1.46% | -17.38% | Jun 2026 |
| Rice Hall James & Associates, LLC | 270K | 1.35% | -4.77% | Jun 2026 |
| Ranger Investment Management LP | 258K | 1.29% | -3.86% | Jun 2026 |
| Northern Trust Corp | 257K | 1.29% | +1.27% | Jun 2026 |
Ligand Pharmaceuticals Incorporated company profile
- Company name
- Ligand Pharmaceuticals Incorporated
- Ticker
- LGND.US
- Exchange
- USA Stocks
- Listed since
- Nov 18, 1992
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 47
- Fiscal year end
- December
- Address
- 555 Heritage Drive, Jupiter, FL, United States, 33458
- Phone
- 858 550 7500
- Website
- ligand.com
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Ligand Pharmaceuticals Incorporated management
10- Mr. Todd C. Davis Ph.D.CEO & Director · born 1961
- Mr. Octavio EspinozaChief Financial Officer · born 1971
- Mr. Andrew T. Reardon J.D.Chief Legal Officer & Secretary · born 1975
- Mr. Paul J. HaddenSenior Vice President of Investments & Business Development
- Ms. Melanie J. Herman CPAExecutive Director of Investor Relations and Financial Planning & Analysis · born 1979
- Ms. Marjorie FackovecHead of People Operations
- Dr. Keith Marschke Ph.D.Senior Vice President of Biology & Scientific Affairs
- Dr. Vincent D. Antle Ph.D.Senior Vice President of Technical Operations & QA - Capitsol · born 1969
- Dr. Karen R. Reeves M.D.Senior VP of Investments & Head of Clinical Strategy · born 1950
- Mr. Richard B. BaxterSenior VP of Investment Operations · born 1963